WESTMINSTER, Colo.--(BUSINESS WIRE)--Cerapedics, Inc., a medical device company focused on developing and commercializing novel osteobiologic products, announced today that it received the CE Mark for ...
Cerapedics' i-FACTOR Peptide Enhanced Bone Graft gets FDA approval for use in cervical spine surgery
Orthobiologics company positioned to begin commercial distribution in the U.S. following successful Premarket Approval application. Cerapedics, a privately-held orthobiologics company, announced today ...
Results published in Neurosurgery show peptide enhanced bone graft statistically superior to autograft in ACDF procedures at two years. "We are pleased that the statistical superiority in overall ...
WESTMINSTER, Colo., March 6, 2019 /PRNewswire/ -- Cerapedics, a privately-held orthobiologics company, today announced that the International Society for the Advancement of Spine Surgery (ISASS) ...
Approval underscores Cerapedics' commitment to investing in evidence that brings scientific rigor to bone grafting for spinal fusion. WESTMINSTER, Colo., Sept. 24, 2024 /PRNewswire/ -- Cerapedics Inc.
WESTMINSTER, Colo., Oct. 26, 2017 /PRNewswire/ -- Cerapedics, a privately-held orthobiologics company, today announced that more than 150 leading U.S. hospitals have now adopted use of i-FACTOR™ ...
WESTMINSTER, Colo.--(BUSINESS WIRE)--Cerapedics, Inc. announced that it recently completed a Series C round of private equity financing totaling $19 million led by new investors MedImmune Ventures and ...
The FDA has approved a biologic bone graft for use in the cervical spine. The i-Factor peptide-enhanced bone graft from Cerapedics Inc., of Westminster, Colo., a private orthobiologics company, got ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results